+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Neuropsychotherapeutics, Vol 86. Advances in Pharmacology

  • ID: 4768598
  • Book
  • August 2019
  • Region: Global
  • 320 Pages
  • Elsevier Science and Technology
1 of 2

Neuropsychotherapeutics, Volume 86, the newest volume in the Advances in Pharmacology series, presents a variety of chapters from the best authors in the field, with this updated edition including sections on Pharmacotherapy of psychiatric disorders, Allosteric mechanisms for neuropsychopharmacology, Lipid rafts, Rapid-acting antidepressants, mGlu2/3 receptor antagonists, Nitric oxide: antidepressant mechanisms and inflammation, Anxiety disorders, mGlu receptors and schizophrenia, mAChR ligands for schizophrenia and addiction, PDE10 inhibitors, Obsessive-compulsive disorder, Addiction disorders (including eating), Dopamine D1 PAMs as a New Mode for Treatment of Neuropsychiatric Disorders, and more.

  • Includes the authority and expertise of leading contributors in pharmacology
  • Presents the latest release in the Advances in Pharmacology series

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Note: Product cover images may vary from those shown
2 of 2
1. GPCR drug discovery-moving beyond the orthosteric to the allosteric domain Christian C. Felder 2. Lipid rafts in psychiatry Nathan H. Wray and Mark M. Rasenick 3. Rapid-acting antidepressants Jeffrey M. Witkin, Anna E. Martin, Lalit K. Golani, Nina Z. Xu and Jodi L. Smith 4. mGlu2/3 receptor antagonists Shigeyuki Chaki 5. Nitric oxide: Antidepressant mechanisms and inflammation Mehdi Ghasemi 6. Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disorders Laura B. Teal, Robert W. Gould, Andrew S. Felts and Carrie K. Jones 7. Medications development for food-based and drug use disorders Fernando B. de Moura, Stephen J. Kohut and Jack Bergman 8. Obsessive compulsive disorder (OCD): Current treatments and a framework for neurotherapeutic research Erik Z. Woody, Kurt Leroy Hoffman and Henry Szechtman 9. Positive allosteric modulators of the dopamine D1 receptor: A new mechanism for the treatment of neuropsychiatric disorders Kjell A. Svensson, Junliang Hao and Robert F. Bruns
Note: Product cover images may vary from those shown
3 of 2